Axsome Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Axsome Therapeutics

04/08/2025 14:31

Axsome Therapeutics Inc AXSM.OQ reported a quarterly adjusted loss of 97 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.67.  The mean expectation of nineteen analysts for the quarter was for a loss of $1.10 per share. Wall Street expected results to range from $-1.26 to -75 cents per share.

Revenue rose 72.1% to $150.04 million from a year ago; analysts expected $138.82 million.

Axsome Therapeutics Inc's reported EPS for the quarter was a loss of 97 cents​.

The company reported a quarterly loss of $47.97 million.

Axsome Therapeutics Inc shares had fallen by 1.3% this quarter and gained 21.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 6.6% in the last three months.​

In the last 30 days, ten analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Axsome Therapeutics Inc is $181.50, about 43.2% above its last closing price of $103.02

This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.10
-0.97
Beat
Mar. 31 2025
-1.33
-1.22
Beat
Dec. 31 2024
-1.02
-1.54
Missed
Sep. 30 2024
-1.41
-1.34
Beat